Cabaletta Bio, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CABA Nasdaq 2834 www.cabalettabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cabaletta Bio, Inc.

Top Midday Decliners - Jun 11th, 2025 12:09 pm
Cabaletta Bio Announces Pricing of Public Offering of Securities - Jun 11th, 2025 7:54 am
Cabaletta Bio Announces Proposed Public Offering of Securities - Jun 11th, 2025 4:15 am
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - Jun 11th, 2025 4:00 am
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference - May 29th, 2025 6:00 am
Biotech Alert: Searches spiking for these stocks today - May 20th, 2025 8:55 am
Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks - May 16th, 2025 6:08 am
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts - May 15th, 2025 5:00 am
Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz - Apr 1st, 2025 10:16 am
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Mar 31st, 2025 5:00 am
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform - Mar 19th, 2025 5:00 am
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference - Feb 26th, 2025 6:00 am
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings - Feb 18th, 2025 8:21 am
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings - Feb 18th, 2025 5:00 am
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February - Feb 11th, 2025 6:00 am
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference - Jan 29th, 2025 6:00 am
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025 - Jan 13th, 2025 6:00 am
Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures - Dec 10th, 2024 3:44 am
Cabaletta Bio to Participate in Upcoming Investor Conferences in December - Nov 26th, 2024 6:00 am
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - Nov 18th, 2024 5:00 am